ClinicalTrials.gg
RecruitingNCT05476991RIISC-THETISUpdated Sep 8, 2025

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

A Phase 3 interventional study of Colchicine 0.5 MG and Ticagrelor 90mg in Stroke, Stroke, Ischemic and Atherosclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing ticagrelor in Stroke — 2 open to participants now, 3 under way, 2 of them phase 3. Ticagrelor · Stroke.

Planned enrollment
5th of 11
2,800 · median 1,875
Started
2023
the only one that year
Phase 3
6 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Assistance Publique - Hôpitaux de Paris

Among the 11 studies testing ticagrelor in Stroke, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

2 of the 11 studies testing ticagrelor in Stroke are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ticagrelor in Stroke, or all of them as a file.
02

Study summary

REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.

Read the detailed description

Our main hypothesis is that low-dose colchicine (0.5 mg/day) on top of best medical care, in patients with an ischemic stroke with ipsilateral atherosclerotic stenosis, will reduce the risk of major vascular events after 36-60 months of treatment as compared to no colchicine.

Our second main hypothesis, tested in 2x2 factorial design, is that ticagrelor 90 mg bid in the same patients, will reduce the long-term risk of major vascular events (after 36-60 months of treatment) as compared to aspirin 75-300 mg/day.

03

Conditions studied

  • Stroke
  • Stroke, Ischemic
  • Atherosclerosis
  • Myocardial Infarction
  • Coronary Syndrome
  • TIA
  • Cardiac Disease
  • Cerebral Infarction

Keywords

  • Stroke
  • Colchicine
  • Atherosclerosis
  • Aspirin
  • Ticagrelor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient should have the following:

Patient with:

  1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event ( with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition)
  2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia/dysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis ≥70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event
  3. and documented atherosclerotic stenosis:

    1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)
    2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)
    3. or presence of atherosclerotic disease of the aortic arch with a plaque ≥4mm in thickness with or without superimposed thrombus, or a plaque \<4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography)
  4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant)
  5. age equal or above 18
  6. Rankin score less than ≤4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death),
  7. fully informed and signed inform consent
  8. with social security number.
  9. medical examination before the participation to the research
  10. Under in case of (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only).
  11. Pregnancy test for women of childbearing potential

Exclusion criteria

Exclusion Criteria:

  1. Colchicine treatment needed (e.g., gout, Mediterranean fever)
  2. to ticagrelor or any of the .
  3. Hypersensitivity to colchicine or any of the excipients.
  4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease)
  5. , medullary aplasia
  6. Active chronic inflammatory disease, chronic active infection, evolving cancer
  7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance)
  8. A recent severe sepsis (7 days) or all recent acute reaches
  9. Chronic treatment (for more than 6 months) with or NSAIDs (or repeated high-dose intake for less than 7 days).
  10. Anticipated concomitant oral or intravenous therapy with strong inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study
  11. CI/ due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met]
  12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation)
  13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called "microbleedings" - on gradient echo imaging is not an exclusion criteria)
  14. Active pathological bleeding
  15. Uncontrolled hypertension (investigator judgement)
  16. Follow-up visit impossible or anticipated bad compliance.
  17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits..
  18. Anticipated pregnancy at time of enrollment in the study
  19. Breastfeeding woman
  20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy.
  21. Leukopenia \<3000/μl
  22. Patients with severe renal impairment ( \< 30 ml/min)
  23. Patients with severe hepatic impairment
  24. Prohibited treatments: All treatments during the use of colchicine and/or ticagrelor
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
2,800 participants (estimated)

Study arms

  • Experimental
    Colchicine + Ticagrelor

    Drug: Colchicine 0.5 MG · Drug: Ticagrelor 90mg

  • Experimental
    Colchine + Aspirine

    Drug: Colchicine 0.5 MG · Drug: Aspirin 75-300mg

  • Experimental
    SOC + Ticagrelor

    Drug: Ticagrelor 90mg

  • Active comparator
    SOC + Aspirine

    Drug: Aspirin 75-300mg

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.

    Also known as: Brilinta

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).

    Also known as: Acetylsalicylic acid

06

What researchers measure

Primary outcomes

  1. Number of Participants with nonfatal ischemic stroke

    Sudden onset of focal neurologic symptoms related to impaired cerebral circulation. ASCOD phenotyping will be used. TIAs will not be part of strokes. However, any focal neurologic symptoms associated with positive DWI or hypodensity on the CT scan in an appropriate area in relation with these symptoms will be considered a cerebral infarction and be part of "strokes".

    Time frame: 36 months

  2. Number of Participants with undetermined stroke

    Sudden onset of focal neurologic symptoms related to impaired cerebral circulation. ASCOD phenotyping will be used. TIAs will not be part of strokes. However, any focal neurologic symptoms associated with positive DWI or hypodensity on the CT scan in an appropriate area in relation with these symptoms will be considered a cerebral infarction and be part of "strokes".

    Time frame: 36 months

  3. Number of Participants with nonfatal myocardial infarction

    * Fatal or nonfatal myocardial infarction (OMS.AHA/ACC definition) o Clinical symptoms + elevated troponin * Silent myocardial infarction following universal definition

    Time frame: 36 months

  4. Number of Participants with urgent coronary or carotid revascularization following new symptoms

    Revascularization Procedure * Coronary : Angioplasty or stenting or CABG * Carotid : angioplasty or stenting, surgical endarterectomy * Peripheral: angioplasty or stenting including aorta, surgical by-pass or endarterectomy of a peripheral artery.

    Time frame: 36 months

  5. Number of Participants with vascular death including sudden death

    \- Vascular death * Death due to cardiac or vascular cause * Death due to systemic hemorrhage * Death due to pulmonary embolism * Sudden death: death occurring within 24 hours, unexpected in a patient in apparent healthy condition or condition that was stable or improved * Death without documented nonvascular cause * Fatal stroke: death occurring within 30 days of stroke onset (whether ischemic or hemorrhagic).

    Time frame: 36 months

Secondary outcomes

  1. Number of Participants with recurrent fatal and nonfatal ischemic stroke

    Time frame: 36 months

  2. Number of Participants with urgent carotid revascularization following a new transient ischemic attack with negative neuro-imaging

    Time frame: 36 months

  3. Number of Participants with fatal and nonfatal myocardial infarction

    Time frame: 36 months

  4. Number of Participants with fatal and nonfatal myocardial infarction or urgent coronary revascularization following a new acute coronary syndrome

    Time frame: 36 months

  5. Number of Participants with vascular death

    Time frame: 36 months

  6. Number of Participants with any stroke or TIA

    A TIA is defined by sudden onset of neurologic symptoms presumed of ischemic origin, with total resolution, being clearly related to focal cerebral or retinal involvement, and with negative neuro-imaging in the cerebral area corresponding to the symptoms. TIA diagnosis must be confirmed by a neurologist, based on clinical and negative neuro-imaging evaluation (MRI with DWI is recommended).

    Time frame: 36 months

  7. Number of Participants with major coronary events

    Time frame: 36 months

  8. Number of Participants with any coronary end-points (MI, hospitalization for recurrent ACS, coronary revascularization procedure urgent or elective, fatal coronary event)

    ACS: Acute Coronary Syndrome

    Time frame: 36 months

  9. Number of death participant (any death)

    Time frame: 36 months

  10. Number of Participant with all revascularization procedures (coronary, carotid, peripheral)

    Time frame: 36 months

  11. Number of Participants with Carotid revascularization

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Sep 2027, 51 months after the start.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 51 months is above that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Jul 27, 2022
StartActual
May 17, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05476991
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
May 17, 2023
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 8, 2025

Study contacts

Pierre Amarenco, Pr
Contact
pierre.amarenco@gmail.com
140258725 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Colchicine · Ticagrelor · Aspirin

Start the discussion